Mezgosal

Esomeprazole, the active ingredient in Mezgosal, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastro‑esophageal reflux disease and ulcers.

GNH USA supplies Mezgosal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Clients benefit from consistent batch release, comprehensive documentation, and responsive technical support throughout the supply chain.

Esomeprazole is indicated for several acid‑related conditions, providing acid suppression to promote healing and symptom relief. - Gastro‑esophageal reflux disease (GERD): alleviates heartburn and regurgitation by reducing gastric acid exposure. - Erosive esophagitis: promotes mucosal healing of inflamed esophageal tissue. - NSAID‑induced gastric ulcer: protects the gastric lining and facilitates ulcer resolution. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by maintaining a less acidic environment.

Esomeprazole is generally well tolerated, but a range of adverse reactions have been reported.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may be self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: discomfort in the stomach region.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Clostridioides difficile infection: colitis associated with altered gut flora. - Hypomagnesemia: low serum magnesium that can cause muscle cramps or cardiac arrhythmia. - Stevens‑Johnson syndrome: rare skin and mucous membrane disorder.

When prescribing esomeprazole, clinicians should consider several safety measures to minimize risk. - Assess renal function: dose adjustment may be required in severe impairment. - Monitor magnesium levels: prolonged use can lead to hypomagnesemia. - Use caution in hepatic impairment: drug metabolism may be altered. - Avoid abrupt discontinuation: taper to prevent rebound acid hypersecretion. - Store at ambient temperature: keep in the original container, protect from moisture.

Esomeprazole can affect the pharmacokinetics of other medicines; awareness of key interactions helps ensure safe co‑administration.

Major Interactions (Avoid): - Ketoconazole: reduced antifungal absorption. - Atazanavir: decreased antiviral efficacy. - Clopidogrel: impaired antiplatelet activation.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect. - Digoxin: possible elevation of serum concentrations. - Methotrexate: reduced renal clearance may raise toxicity risk.